Want to see IN:AARTIPHARM full AI Analyst Report?
AARTIPHARM Stock Chart & Stats
₹842.40
₹9.55(1.45%)
At close: 4:00 PM EST
₹842.40
₹9.55(1.45%)
Day’s Range― - ―
52-Week Range₹583.85 - ₹969.05
Previous CloseN/A
Volume141.60K
Average Volume (3M)18.67K
Market Cap
₹65.08B
Enterprise Value₹66.21B
Total Cash (Recent Filing)₹96.16M
Total Debt (Recent Filing)₹7.54B
Price to Earnings (P/E)34.4
Beta0.89
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)20.57
Shares Outstanding90,679,810
10 Day Avg. Volume12,195
30 Day Avg. Volume18,670
Financial Highlights & Ratios
PEG Ratio-0.92
Price to Book (P/B)2.71
Price to Sales (P/S)3.16
P/FCF Ratio-30.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API And Intermediate ManufacturingA B2B API/intermediate manufacturing model delivers durable demand from formulators and specialty chemical customers. Long-term supply contracts and volume-based pricing create repeatable revenues tied to production scale and customer relationships, supporting stable cash generation over months.
Process Chemistry And Industrial-scale CapabilityCore expertise in process chemistry and industrial-scale manufacturing is a structural competitive advantage. It enables production of complex/advanced intermediates, higher yields, and cost efficiencies that are hard to replicate, supporting durable market position and margin resilience versus smaller competitors.
Historically Solid Margins And ProfitabilitySustained healthy operating and net margins across FY2023–FY2025 indicate an ability to capture value in its product mix. This historical profitability provides buffer during cyclicality and supports reinvestment capacity and creditor confidence if management stabilizes near-term performance.
Bears Say
FY2026 Revenue And Earnings WeaknessA decline in revenue (~4.5% YoY) and sharply lower net income in FY2026 signal weakening demand, margin pressure or pricing erosion. Over a multi-month horizon this reduces internal cash generation, stresses margins, and complicates efforts to deleverage or fund investments without external support.
Material Increase In LeverageA marked rise in borrowings and leverage erodes balance-sheet flexibility and raises fixed interest obligations. If earnings remain pressured, higher leverage increases refinancing and solvency risk, limiting room for opportunistic capex or working-capital cushions over the coming quarters.
Negative Free Cash Flow TrendMeaningful negative free cash flow across FY2025–FY2026 suggests elevated capex or working-capital strain and reliance on external funding. Persistent negative FCF undermines self-funded growth, increases funding costs, and heightens vulnerability to funding shocks if margins or volumes weaken further.
Aarti Pharmalabs Limited News
AARTIPHARM FAQ
What was Aarti Pharmalabs Limited’s price range in the past 12 months?
Aarti Pharmalabs Limited lowest stock price was ₹583.85 and its highest was ₹969.05 in the past 12 months.
What is Aarti Pharmalabs Limited’s market cap?
Aarti Pharmalabs Limited’s market cap is ₹65.08B.
When is Aarti Pharmalabs Limited’s upcoming earnings report date?
Aarti Pharmalabs Limited’s upcoming earnings report date is Aug 03, 2026 which is in 16 days.
How were Aarti Pharmalabs Limited’s earnings last quarter?
Aarti Pharmalabs Limited released its earnings results on May 25, 2026. The company reported ₹6.74 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.74.
Is Aarti Pharmalabs Limited overvalued?
According to Wall Street analysts Aarti Pharmalabs Limited’s price is currently Overvalued.
Does Aarti Pharmalabs Limited pay dividends?
Aarti Pharmalabs Limited pays a Semiannually dividend of ₹1.5 which represents an annual dividend yield of 0.67%. See more information on Aarti Pharmalabs Limited dividends here
What is Aarti Pharmalabs Limited’s EPS estimate?
Aarti Pharmalabs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Pharmalabs Limited have?
Aarti Pharmalabs Limited has 90,679,810 shares outstanding.
What happened to Aarti Pharmalabs Limited’s price movement after its last earnings report?
Aarti Pharmalabs Limited reported an EPS of ₹6.74 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.666%.
Which hedge fund is a major shareholder of Aarti Pharmalabs Limited?
Currently, no hedge funds are holding shares in IN:AARTIPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
FDC Ltd.
―
Gufic Biosciences Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Orchid Pharma Limited
―